Zhongqiang Pharmaceutical
R&D of high-end generics and innovative drugs
About Zhongqiang Pharmaceutical
Shanghai ForeFront Pharmaceutical Co., Ltd. is a research and development-driven biopharmaceutical company based in Shanghai, China. The company initially focused on high-end generics and is now expanding into the development of innovative drugs, particularly in the areas of orphan drugs and anticancer treatments.
ForeFront Pharma's portfolio includes difficult-to-synthesize molecules, innovative drug delivery systems like controlled and sustained-release formulations, and fixed-dose combination technologies. The company is active in therapeutic areas such as oncology, anti-inflammation, antiviral, cardiovascular (CVS), and central nervous system (CNS) diseases. Their strategy involves filing for Paragraph IV and 505(b)(2) applications in the US and EU, as well as Category 1, 3, and 4 drug applications in China, both independently and through strategic partnerships. The firm's services also extend to contract research and development, including preformulation, formulation development, and regulatory support.
The company has established a capable R&D team and utilizes sophisticated equipment to support its operations. Its product list includes intermediates and finished drug products for molecules such as Treprostinil, Sapropterin, Selexipag, Sofosbuvir/Velpatasvir, and Ledipasvir, among others.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 18.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Oncology, Drug Development, Pharmaceutical, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Dec 2025 | $14M | $55M | Shenzhen Capital Group · China Grand Pharmaceutical and Healthcare Holdings · Zhongzhe Venture Capital | ↗ |
Growth signals
Latest recorded traffic for Zhongqiang Pharmaceutical is 540 monthly website visits, up 1700% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Zhongqiang Pharmaceutical in its local ecosystem
The Zhongqiang Pharmaceutical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Shenzhen Capital Group
China Grand Pharmaceutical and Healthcare Holdings- ZCZhongzhe Venture Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Zhongqiang Pharmaceutical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Zhongqiang Pharmaceutical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










